Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1531 to 1545 of 2105 results for technology appraisal

  1. Content assurance service

    Our content assurance service. Includes what the service offers, how to apply and pricing.

  2. Assessing the resource impact of NICE guidance

    We estimate the costs or savings (resource impact) associated with technologies and guidelines so you can plan for and implement guidance.

  3. Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause (TA1143)

    Evidence-based recommendations on fezolinetant (Veoza) for treating moderate to severe vasomotor symptoms associated with menopause.

    Technology appraisal guidance
    Published
    31 March 2026

    Sections for TA1143

  4. Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    discretion).• Discuss the outcomes of the procedure during their annual appraisal to reflect, learn and improve. Healthcare...

    Research recommendation
    Published
    30 September 2022

  5. Evidence on the safety of the swallowable gastric balloon capsule for weight loss shows infrequent but potentially serious adverse events: For people who need to lose weight in the short term for medical reasons, the evidence of efficacy is adequate to support the use of this procedure provided that special arrangements are in place for clinical governance, consent and audit.  Find out  what special arrangements mean on the NICE interventional procedures guidance page . For people who are aiming for long-term weight loss, the evidence on efficacy is inadequate in quantity and quality, so the procedure should only be used in the context of research.   Find out  what only in research means on the NICE interventional procedures guidance page .

    discretion). Discuss the outcomes of the procedure during their annual appraisal to reflect, learn and improve. 1.3 Further research...

    Research recommendation
    Published
    22 January 2021

  6. MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes (MIB51)

    NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes

    Medtech innovation briefing
    Published
    12 February 2016

  7. Interim methods guide for developing good practice guidance (PMG15)

    This interim methods guide is based on the general principles and methods included in other methods guides for developing NICE guidance

  8. ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)

    NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .

    Medtech innovation briefing
    Published
    10 May 2022

  9. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder (TA292)

    Evidence-based recommendations on aripiprazole for treating moderate to severe manic episodes in young people with bipolar I disorder.

    Technology appraisal guidance
    Published
    24 July 2013
    View recommendations

    Sections for TA292

  10. The evidence for treating an acute migraine attack is adequate but, for treating subsequent attacks, is limited in quality and quantity. So, for treating acute migraine, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page . The evidence for preventing migraine is inadequate in quality. So, for preventing migraine, this procedure should only be used in the context of research. Find out what only in research means on the NICE interventional procedures guidance page.

    discretion). Discuss the outcomes of the procedure during their annual appraisal to reflect, learn and improve. Healthcare organisations...

    Research recommendation
    Published
    7 November 2022

  11. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.

    HealthTech guidance
    Published
    21 June 2017
    View recommendations

    Sections for HTG441

  12. Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)

    This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs

  13. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus (TA151)

    Evidence-based recommendations on continuous subcutaneous insulin infusion (insulin pump therapy) for treating type 1 diabetes in adults and children.

    Technology appraisal guidance
    Published
    23 July 2008
    View recommendations

    Sections for TA151

  14. Belzutifan for treating tumours associated with von Hippel-Lindau disease (TA1011)

    Evidence-based recommendations on belzutifan (Welireg) for treating tumours associated with von Hippel-Lindau disease in adults.

    Technology appraisal guidance
    Published
    16 October 2024
    View recommendations

    Sections for TA1011

  15. Voclosporin with mycophenolate mofetil for treating lupus nephritis (TA882)

    Evidence-based recommendations on voclosporin (Lupkynis) with mycophenolate mofetil for treating lupus nephritis in adults.

    Technology appraisal guidance
    Published
    3 May 2023
    View recommendations

    Sections for TA882